XML 61 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Discontinued operations | 12 Months Ended
--- | ---
Dec. 31, 2024
Discontinued operations |
Discontinued operations | 28. Discontinued operations The transactions of Oxiteno and Extrafarma sale were concluded on April 1, 2022 and August 1, 2022, respectively. The Company accounted for the disposal of investments in accordance with the international standard IFRS 5 ‐ Non-current Assets Held for Sale and Discontinued Operations, which require recognizing any assets and liabilities as “Held‐for‐sale assets” and “Liabilities related to held‐for‐sale assets” in the balance sheet and reporting the income (loss) of the companies sold up to the sale date, as well as the gain (loss) from the sale of the investments, as “Discontinued operations” in the statement of income. The divestments of Oxiteno and Extrafarma are aligned with Ultrapar's portfolio review. With a more complementary and synergistic businesses, Ultrapar concludes the rationalization phase of its portfolio and will now concentrate on developing investment opportunities in the verticals of energy and infrastructure, with increasing focus on energy transition, leveraged by its portfolio and expertise. In this context, the Company announced in 2021 the contracts signing described below and classified these transactions as discontinued operations. The tables of discontinued operation are detailed below and include the profit or loss incurred throughout 2022, when applicable. Eliminations refer to intercompany transactions, substantially represented by purchase and sale transactions, effects on the profit or loss of foreign debts contemplating hedging instruments, among others. a. The results and cash flows from discontinued operations for the year ended December 31, 2022, are shown below:
| Oxiteno |  |  | Extrafarma |  |  | Eliminations (*) |  |  | Ultrapar |  |  | 12/31/2022 |
Net revenue from sales and services | 2,039,287 |  |  | 1,235,487 |  |  | (7,241 | ) |  | ‐ |  |  | 3,267,533 |
Cost of products and services sold | (1,580,000 | ) |  | (912,310 | ) |  | 7,241 |  |  | ‐ |  |  | (2,485,069 | )
Gross profit | 459,287 |  |  | 323,177 |  |  | ‐ |  |  | ‐ |  |  | 782,464 |
Selling, marketing and administrative | (201,365 | ) |  | (438,601 | ) |  | ‐ |  |  | ‐ |  |  | (639,966 | )
Other operating income (expenses), net | 10,736 |  |  | (5,951 | ) |  | ‐ |  |  | 241,325 |  |  | 246,110 |
Operating income (loss) | 268,658 |  |  | (121,375 | ) |  | ‐ |  |  | 241,325 |  |  | 388,608 |
Share of profit (loss) of subsidiaries, joint ventures and associates | (231 | ) |  | ‐ |  |  | ‐ |  |  | ‐ |  |  | (231 | )
Income (loss) before financial result and income and social contribution taxes | 268,427 |  |  | (121,375 | ) |  | ‐ |  |  | 241,325 |  |  | 388,377 |
Financial result, net | 23,153 |  |  | (25,059 | ) |  | 54,431 |  |  | ‐ |  |  | 52,525 |
Income (loss) before income and social contribution taxes | 291,580 |  |  | (146,434 | ) |  | 54,431 |  |  | 241,325 |  |  | 440,902 |
Income and social contribution taxes | (16,924 | ) |  | 20,826 |  |  | (18,507 | ) |  | (202,895 | ) |  | (217,500 | )
Net effect of cessation of depreciation (i) | 51,372 |  |  | 27,084 |  |  | ‐ |  |  | ‐ |  |  | 78,456 |
Net income (loss) for the year | 326,028 |  |  | (98,524 | ) |  | 35,924 |  |  | 38,430 |  |  | 301,858 |
(*) | Elimination between continuing and discontinued operations related to the intercompany loan between Ultrapar International and Oxiteno.
(i) | As of January 1, 2022, the depreciation and amortization of assets classified as held for sale ceased, in compliance with item 25 of IFRS 5.
| Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | 12/31/2022 |
Net cash (consumed) provided by operating activities | (81,558 | ) |  | (68,370 | ) |  | 180,478 |  |  | 30,550 |
Net cash (consumed) provided by investing activities | 1,011,736 |  |  | (25,323 | ) |  | (1,206,603 | ) |  | (220,190 | )
Net cash (consumed) provided by financing activities | (1,245,754 | ) |  | 40,585 |  |  | 1,026,144 |  |  | (179,025 | )
Effect of exchange rate variation on cash and cash equivalents in foreign currency | (19,316 | ) |  | ‐ |  |  | ‐ |  |  | (19,316 | )
Increase (decrease) in cash and cash equivalents | (334,892 | ) |  | (53,108 | ) |  | 19 |  |  | (387,981 | )
In the Parent, the proceeds from the sale of Oxiteno and the share of profit (loss) of investees Oxiteno and Extrafarma, net of transactions with related parties, had an impact of R$ 301,858 in 2022, classified as income from discontinued operations in the consolidated financial statements.

X
- Definition The entire disclosure for non-current assets held for sale and discontinued operations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2024-01-01 -Section Presentation and disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration